The search result changed since you submitted your search request. Documents might be displayed in a different sort order.
  • search hit 93 of 2873
Back to Result List

Antimycobacterial activity of the extract and isolated compounds from the stem bark of Zanthoxylum leprieurii Guill. and Perr.

  • Zanthoxylum leprieurii Guill. and Perr. (Rutaceae) stem bark is used locally in Uganda for treating tuberculosis (TB) and cough-related infections. Lupeol (1), sesamin (2), trans-fagaramide (3), arnottianamide (4), (S)-marmesinin (5), and hesperidin (6) were isolated from the chloroform/methanol (1:1) extract of Z. leprieurii stem bark. Their structures were elucidated using spectroscopic techniques and by comparison with literature data. Furthermore, the extract and isolated compounds were subjected to antimycobacterial activity. The extract exhibited moderate activity against the susceptible (H(37)Rv) TB strain, but weak activity against the multidrug resistant (MDR)-TB strain with minimum inhibitory concentrations (MICs) of 586.0 and 1172.0 mu g/mL, respectively. Compound 3 (trans-fagaramide) showed significant antimycobacterial activity against the susceptible (H(37)Rv) TB strain (MIC 6 mu g/mL), but moderate activity against the MDR-TB strain (MIC 12.2 mu g/mL). Compounds 2, 5, 6, and 1 showed moderate activities against theZanthoxylum leprieurii Guill. and Perr. (Rutaceae) stem bark is used locally in Uganda for treating tuberculosis (TB) and cough-related infections. Lupeol (1), sesamin (2), trans-fagaramide (3), arnottianamide (4), (S)-marmesinin (5), and hesperidin (6) were isolated from the chloroform/methanol (1:1) extract of Z. leprieurii stem bark. Their structures were elucidated using spectroscopic techniques and by comparison with literature data. Furthermore, the extract and isolated compounds were subjected to antimycobacterial activity. The extract exhibited moderate activity against the susceptible (H(37)Rv) TB strain, but weak activity against the multidrug resistant (MDR)-TB strain with minimum inhibitory concentrations (MICs) of 586.0 and 1172.0 mu g/mL, respectively. Compound 3 (trans-fagaramide) showed significant antimycobacterial activity against the susceptible (H(37)Rv) TB strain (MIC 6 mu g/mL), but moderate activity against the MDR-TB strain (MIC 12.2 mu g/mL). Compounds 2, 5, 6, and 1 showed moderate activities against the susceptible (H(37)Rv) strain (MIC 12.2-98.0 mu g/mL) and moderate to weak activities against the MDR-TB strain (MIC 24.4-195.0 mu g/mL). This study reports for the first time the isolation of compounds 1 to 6 from the stem bark of Z leprieurii. trans-Fagaramide (3) may present a vital template in pursuit of novel and highly effective TB drugs.show moreshow less

Export metadata

Additional Services

Search Google Scholar Statistics
Metadaten
Author details:Benson OloyaORCiD, Jane Namukobe, Matthias HeydenreichORCiD, Willy SsengoobaORCiD, Bernd SchmidtORCiD, Robert Byamukama
DOI:https://doi.org/10.1177/1934578X211035851
ISSN:1934-578X
ISSN:1555-9475
Title of parent work (English):Natural product communications : an international journal for communications and reviews
Publisher:Sage Publ.
Place of publishing:Thousand Oaks
Publication type:Article
Language:English
Date of first publication:2021/08/24
Publication year:2021
Release date:2023/12/11
Tag:Zanthoxylum leprieurii; alkaloid; antimycobacterial activity; trans-fagaramide; tuberculosis
Volume:16
Issue:8
Article number:1934578X211035851
Number of pages:8
Funding institution:Deutscher Akademischer Austauschdienst (DAAD)Deutscher Akademischer Austausch Dienst (DAAD) [91560246]; DAADDeutscher Akademischer Austausch Dienst (DAAD)European Commission
Organizational units:Mathematisch-Naturwissenschaftliche Fakultät / Institut für Chemie
DDC classification:5 Naturwissenschaften und Mathematik / 54 Chemie / 540 Chemie und zugeordnete Wissenschaften
Peer review:Referiert
Publishing method:Open Access / Gold Open-Access
DOAJ gelistet
License (German):License LogoCC-BY-NC - Namensnennung, nicht kommerziell 4.0 International
Accept ✔
This website uses technically necessary session cookies. By continuing to use the website, you agree to this. You can find our privacy policy here.